Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Neurology
Published in: Journal of Neurology 2/2015

Open Access 01-02-2015 | Review

Overview of neurosarcoidosis: recent advances

Authors: Renata Hebel, Mirosława Dubaniewicz-Wybieralska, Anna Dubaniewicz

Published in: Journal of Neurology | Issue 2/2015

Login to get access

Abstract

Sarcoidosis (SA) is a granulomatous, multisystem disease of unknown etiology. Most often the disease affects lungs and mediastinal lymph nodes, but it may occur in other organs. Neurosarcoidosis (NS) more commonly occurs with other sarcoidosis forms, in 1 % of cases it involves only nervous system. Symptomatic NS occurs but on autopsy study up to 25 % of cases are confirmed. NS can affect central nervous system: the brain, spinal cord and peripheral nerves, and muscles. The diagnosis of neurosarcoidosis facilitates diagnostic criteria: histopathological, imaging and cerebrospinal fluid examination, and clinical symptoms. At present, there are no set standards for treatment of patients suffering from NS. Early therapy of symptomatic patients is recommended. Corticosteroids still are the first line of treatment for NS patients. In cases of steroids resistance, lack of their effectiveness or existence of contraindication to their use, immunosuppressant treatment is recommended. The latest NS algorithm with immunosuppressive treatment is discussed.
Literature
1.
Hunninghake GW, Costabel U, Ando M et al (1999) ATS/ERS WASOG statement on sarcoidosis. ATS/ERS WASOG Sarcoidosis Vasc Diffuse Lung Dis 16:149–173PubMed
2.
3.
Baughman RP, Teirstein AS, Judson MA et al (2011) Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 164:1885–1889CrossRef
4.
Dastoori M, Fedele S, Leao J et al (2013) Sarcoidosis a clinically orientated review. J Oral Pathol Med 42:281–289CrossRefPubMed
5.
Dubaniewicz A (2008) Sarkoidoza-choroba o wielu twarzach. Forum Med Rodz 27–26
6.
Judson MA, Baughman RP, Terstein AS et al (1999) Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. Sarcoidosis Vasc Diffuse Lung Dis 16:75–86PubMed
7.
Dubaniewicz A (2013) Microbial and human heat shock proteins as ‘danger signals’ in sarcoidosis. Hum Immunol 74:1550–1558CrossRefPubMed
8.
Matzinger P (1994) Tolerance, danger, and the extended family. Ann Rev Immunol 12:991CrossRef
9.
Oswald-Richter KA, Beachboard DC, Zhan X et al (2010) Multiple mycobacterial antigens are targets of the adaptive immune response in pulmonary sarcoidosis. Respir Res 23(11):161CrossRef
10.
Negi M, Takemura T, Guzman J et al (2012) Localization of Propionibacterium acnes in granulomas supports a possible etiologic link between sarcoidosis and the bacterium. Mod Pathol 25:1284–1297PubMedCentralCrossRefPubMed
11.
12.
Post J, Hull P (2012) Tattoo reactions as a sign of sarcoidosis. CMAJ 184:43CrossRef
13.
Izbicki G, Chavko R, Banauch GI et al (2007) World trade center “sarcoid-like” granulomatous pulmonary disease in New York city fire department rescue workers. Chest 131:1414–1423CrossRefPubMed
14.
Bargagli E, Magi B, Olivieri C et al (2011) Analysis of serum amyloid a in sarcoidosis patients. Respir Med 105:775–780CrossRefPubMed
15.
Maertzdorf J, Weiner J 3rd, Mollenkopf HJ et al (2012) Common patterns and disease-related signatures in tuberculosis and sarcoidosis. Proc Natl Acad Sci USA 109:7853–7858PubMedCentralCrossRefPubMed
16.
Sobic-Saranovic D, Artiko V, Obradovic V (2013) FDG PET imaging in sarcoidosis. Semin Nucl Med 43:404–411CrossRefPubMed
17.
Mostard RL, van Kroonenburgh GM, Drent M (2013) The role of the PET scan in the management of sarcoidosis. Curr Opin Pulm Med 19:538–544CrossRefPubMed
18.
Ginat D, Dhillon G, Almast J (2011) Magnetic resonance imaging of neurosarcoidosis. J Clin Imag Sci 1:15
19.
Khoury J, Wellik KE, Demaerschalk B (2009) Cerebrospinal fluid angiotensin-converting enzyme for diagnosis of central nervous system sarcoidosis. Neurol 15:108–111CrossRef
20.
21.
Nozaki K, Judson MA (2012) Neurosarcoidosis: clinical manifestations, diagnosis and treatment. Presse Med 41:e331–e348CrossRefPubMed
22.
Diab K, Bhatt J, Wilkes D et al (2013) Clinical manifestations, diagnosis, and treatment of neurosarcoidosis: a review of 39 patients. Chest 130:128S
23.
24.
Gascon-Bayarri J, Mana J, Martinez-Yelamos S et al (2011) Neurosarcoidosis report of 30 cases and a literature survey. Eur J Intern Med 22:E125–E132CrossRefPubMed
25.
Hoitsma E, Faber CG, Drent M et al (2004) Neurosarcoidosis: a clinical dilemma. Lancet Neurol 3:397–407CrossRefPubMed
26.
Nikolakaki E, Kalamafkianaki K, Kouroumalos N et al (2008) Neurosarcoidosis, a rare disease of the CNS. Two case reports. J Neurol 255:137
27.
Joseph FG, Scolding NJ (2009) Neurosarcoidosis: a study of 30 new cases. J Neurol Neurosurg Psychiatry 80:297–304CrossRefPubMed
28.
29.
30.
31.
Goday S, Komerally SL, Arora R (2009) Spinal neurosarcoidosis. J Gen Intern Med 24:353–354
32.
Varron L, Broussolle C, Candessanche JP et al (2009) Spinal cord sarcoidosis: report of seven cases. Eur J Neurol 16:289–296CrossRefPubMed
33.
Powers WJ, Miller FM (1981) Sarcoidosis mimicking glioma: case report and review of intercranial sarcoidosis like mass lesions. Neurology 31:907–910CrossRefPubMed
34.
Reske D, Petereit HF, Heiss WD (2005) Difficulties in the differentiation of chronic inflammatory diseases of the central nervous system—value of cerebrospinal fluid analysis and immunological abnormalities in the diagnosis. Acta Neurol Scand 112:207–213CrossRefPubMed
35.
Marangoni S, Arentiero V, Taolato B (2006) Clinical description of 7 cases with proposal for new diagnosis strategy. J Neurol 253:488–495CrossRefPubMed
36.
37.
Segal BM (2013) Neurosarcoidosis: diagnostic approaches and therapeutic strategies. Curr Opin Neurol 26:307–313CrossRefPubMed
38.
Wengert O, Rothenfusser-Korber E, Vollrath B et al (2013) Neurosarcoidosis: correlation of cerebrospinal fluid findings with diffuse leptomeningeal gadolinium enhancement on MRI and clinical disease activity. J Neurol Sci 335:124–130CrossRefPubMed
39.
Shah R, Roberson GH, Cure JK (2009) Correlation of MR imaging findings and clinical manifestations in neurosarcoidosis. Am J Neuroradiol 30:953–961CrossRefPubMed
40.
Huang JF, Aksamit AJ, Staff NP (2012) MRI and PET imaging discordance in neurosarcoidosis. Neurology 79:1070CrossRefPubMed
41.
Bartels S, Kyavar L, Blumstein N et al (2013) FDG PET findings leading to diagnosis of neurosarcoidosis. Clin Neurol Neurosurg 115:85–88CrossRefPubMed
42.
Kim SK, Im HJ, Kim W et al (2010) F-18 Fluorodeoxyglucose and F-18 fluorothymidine positron emission tomography/computed tomography imaging in a case of neurosarcoidosis. Clin Nucl Med 35:67–70CrossRefPubMed
43.
Meenakshi M, Arnold C, Broadley SA (2012) The value of 18F -fluorodeoxyglucose-positron emission tomography/CT scanning in the diagnosis of neurosarcoidosis. J Clin Neurol Sci 19:1461–1462
44.
Suga K, Matsunaga N, Yasuhiko K et al (2011) F-18 FDG PET/CT findings in a case of spinal cord sarcoidosis. Clin Nucl Med 36:382–385CrossRefPubMed
45.
46.
Vinas FC, Rengachary S (2001) Diagnosis and management of neurosarcoidosis. J Clin Neurol Sci 8:505–513
47.
Bolat S, Berding G, Dengler R et al (2009) Fluorodeoxyglucose positron emission tomography (FDG-PET) is useful in the diagnosis of neurosarcoidosis. J Neurol Sci 287:257–259CrossRefPubMed
48.
49.
50.
51.
Zajicek JP, Scolding NJ, Foster O et al (1999) Central nervous system sarcoidosis—diagnosis and management. QJM 92:103–117CrossRefPubMed
52.
Lower EE, Broderick JP, Brott TG, Baughman RP (1997) Diagnosis and management of neurological sarcoidosis. Arch Intern Med 157:1864–1868CrossRefPubMed
53.
Agbogu BN, Stern BJ, Sewell C et al (1998) Therapeutic considerations in patients with refractory neurosarcoidosis. Arch Neurol 52:875–879CrossRef
54.
Haubitz M, Schellong S, Gobel U et al (1998) Intravenous pulse administration of cyclophosphamide vs daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthr Rheum 41(10):1835–1844CrossRef
55.
Lewis SJ, Ainslie GM, Bateman ED (1999) Efficacy of azathioprine as second-line treatment in pulmonary sarcoidosis. Class IV evidence. Sarcoidosis Vasc Diffuse Lung Dis 16:87–92PubMed
56.
Vorselaars AD, Wuyts WA, Vorselaars VM et al (2013) Methotrexat vs azathioprine in second line therapy of sarcoidosis. Chest 144:805–812CrossRefPubMed
57.
Baughman RP, Lower EE (2005) Therapy for sarcoidosis. Eur Respir Mon 32:301–315
58.
Marnane M, Lynch T, Scott J et al (2009) Steroid-unresponsive neurosarcoidosis successfully treated with adalimumab. J Neurol 256:139–140CrossRefPubMed
59.
Sharma OP (1997) Neurosarcoidosis: a personal perspective based on the study of 37 patients. Chest 112:220–228CrossRefPubMed
60.
61.
Bruns F, Pruemer B, Haverkamp U et al (2004) Neurosarcoidosis: an unusual indication for radiotherapy. Br J Radiol 77:777–779CrossRefPubMed
62.
Chapelon C, Ziza JM, Piette JC et al (1990) Neurosarcoidosis: signs, course and treatment in 35 confirmed cases. Medicine (Baltimore) 69:261–276CrossRef
Metadata
Title
Overview of neurosarcoidosis: recent advances
Authors
Renata Hebel
Mirosława Dubaniewicz-Wybieralska
Anna Dubaniewicz
Publication date
01-02-2015
Publisher
Springer Berlin Heidelberg
Published in
Journal of Neurology / Issue 2/2015
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-014-7482-9

Other articles of this Issue 2/2015

Journal of Neurology 2/2015 Go to the issue

Original Communication

Natural history of skeletal muscle involvement in myotonic dystrophy type 1: a retrospective study in 204 cases

Original Communication

Correlates of cerebrospinal fluid levels of oligomeric- and total-α-synuclein in premotor, motor and dementia stages of Parkinson’s disease

Original Communication

Characterization of sleep disorders in patients with E200K familial Creutzfeldt–Jakob disease

Original Communication

The impact of subthalamic deep brain stimulation on caregivers of Parkinson’s disease patients: an exploratory study

Letter to the Editors

Pompe disease presenting as an isolated generalized dilative arteriopathy with repeated brain and kidney infarcts

Letter to the Editors

The cholinergic basal forebrain in Lewy body dementia and Alzheimer’s disease